Organogenesis Holdings Inc (ORGO) said after close Thursday that it earned $0.01 per share in quarter four 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.
On the revenue line, the company reported $99.7 million, missing estimates by $9.4 million.
In the same quarter a year ago, the company earned $0.07 per share on revenue of $115.5 million.
The stock is down 24.09% to $2.71 after the report.
Organogenesis Holdings Inc's profit margins took a hit as earnings fell at a faster pace than revenues.
Wall Street Analysts had an average rating of Buy on the stock prior to the report.
InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.
Organogenesis Holdings Inc has performed a little above average during the past few months. Before the report, Organogenesis Holdings Inc received a Long-Term Technical Rank by InvestorsObserver of 55, putting it in the top half of stocks. The firm was recently trading at a 52-week high of $4.71 on January 8, 2024 and set a 52-week low on April 26, 2023 at $1.8.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
News Home
Organogenesis Holdings Inc Down 24.09% To $2.71 After Earnings Meet
Mentioned in this article
